[250 Pages Report] In 2021, the Global Heart Block Therapeutics market was estimated to be worth around US$ 3 Billion. With the increasing expenditure incurred on Heart Block Therapeutics worldwide, the market is expected to reach a worth of about US$ 4.8 Billion by the end of 2032, with a projected CAGR of 4.3% during 2022 to 2032. During 2015 to 2021, the Heart Block Therapeutics Market experienced a growth of 4.9%.
| Attributes | Details |
|---|---|
| Global Heart Block Treatment Market Size (2021) | US$ 3.0 Billion |
| Global Heart Block Therapeutics Market Size (2022) | US$ 3.1 Billion |
| Projected Market Value (2032) | US$ 4.8 Billion |
| Global Market Growth Rate (2022 to 2032) | 4.3% CAGR |
| United States Growth Rate (2022 to 2032) | 4.1% CAGR |
| Heart Block Treatment Market Share of Top 5 Countries | 56.1% |
| Key Companies Profiled |
|
In recent years, one of the most rapidly increasing life threating diseases is coronary heart blockage. According to the World Health Organization (WHO), four out of five cardiovascular sickness deaths can be attributed to coronary heart attacks and strokes. Heart attack is considered to be one of the primary reasons for death across the globe.
According to the United Nations Department of Economic and Social Affairs, by 2050, the population of 60 years old and above is expected to reach 437 Mn in China, 324 Mn in India, 107 Mn in The US, and 58 Mn in Brazil. Hence, the growing older populace propels the worldwide Heart Block Therapeutics market as the older population is more prone to heart-related diseases. The World Health Organization (WHO) reported that around 524 Mn people represent the geriatric population in 2010 and by 2050, almost 2 Bn people will be geriatric.
Heart Block Treatment Devices Market is expanding with an expected CAGR of 4.3% in the next ten years. However, due to the huge costs involved in the Heart Block Therapeutics, and restrictions in the availability of advanced resources and technologies, the Heart Block Treatment Industry in various underdeveloped nations is still struggling to expand.
The developing aid infrastructure additionally as a genetic disease is also lifting the growth of heart block treatment market in the higher direction. Also, the rising prevalence of heart blockage cases additionally as increasing incidence of hypothyroidism, which frequently ends up in heart blocks is additionally one amongst the numerous factors supply growth of the Heart Block Therapeutics market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
North America leads the demand for Heart Block Therapeutics in terms of having the largest market for the Heart Block Therapeutics Market due to the increasing cases of cardiovascular diseases in the region. Around 805 thousand people in the US have heart attacks every year. The US spends more than US$ 320 Bn annually which is 15% of their total healthcare spending to manage and treat cardiovascular diseases and cardiovascular risk factors.
Recently, the U.S. Food and Drug Administration announced the approval of Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. Farxiga in a clinical trial showed to improve survival of heart attack patients and reduce the need for hospitalization in adults with heart failure with reduced ejection fraction.
Asia Pacific is the most optimistic market for Heart Block Treatment due to massive population with high unmet medical needs. Around 58% of the total number of heart attack deaths occur in Asia Pacific alone.
China and India have the most promising market for Heart Block Therapeutics. Besides, there have also been significant investments from the government to several large companies in the recent years.
The PEACE MPP is a government-funded public health programme which focuses on cardiovascular disease risk in China. Health Technology firm Abbott has two training centres in China to better serve the Chinese Cardiovascular Patients. Abbott has also made investments into clinical research that will help Chinese doctors complete their projects in the cardiovascular research. The Indian healthcare system has been using advanced technology and artificial intelligence to perform heart treatments. For instance, in India Medtronic launched the Arctic Front Cardiac Cryoablation Catheter System, a cryoballoon catheter approved by the Central Drugs Standard Control Organisation (CDSCO) for the treatment of atrial fibrillation (AF) in India.?
The United States has the largest market for Heart Block Therapeutics, which is projected to reach a valuation of US$ 1.7 Bn by 2032. From 2015 to 2021, the market in the US grew at a CAGR of 4.7%. Between 2022 and 2032, the US is expected to be a market with a US$ 570.5 Mn absolute dollar opportunity for heart block treatment.
In 2015, The American Heart Association invested US$ 3.9 Bn for advanced research in Heart Block Therapeutics. The United States Centres with WHO launched the Global Hearts Initiative in September 2016, which includes the Heart technical package. The package has six modules including healthy-lifestyle counselling, evidence-based treatment protocols, access to essential medicines and technology, risk-based management, team-based care, and systems for monitoring. It provides a strategic approach to improve cardiovascular health in U.S. as well as other countries across the world.
In 2021, China was the second-largest Heart Block Therapeutics Market after the US. The market in the country is expected to reach a valuation of US$ 344 Mn by 2032. In China, coronary bypass surgery, ONCAB, OPCAB, and heart valve replacement devices are all frequently used, resulting in significant growth in the cardiology market.
Heart disease-causing variables such as hypertension, diabetes, excessive alcohol use, cholesterol, and smoking are all on the rise in the region. Guidewires, catheters, radial closure devices, micro guidewires, and stent delivery catheters are among the most extensively used cardiology products in China. The country can additionally explore the Heart Block Therapeutics industry due to favourable government rules and policies.
Principal Consultant
Growing incidence and prevalence rate of hypertension, high cholesterol, diabetes, smoking, obesity, unhealthy dietary plans and older population across the world, government initiatives to increase the awareness toward heart related diseases are the key driving factors in Heart Block Therapeutics Market.
Although one out of every five First Degree Heart blocks require serious medical help, treatment for First Degree Heart Blocks were the most demanded with a CAGR of 5% during 2015-2021. The market through this category is expected to remain the treatment service that will generate the most revenue for the market in the upcoming years with an expected CAGR of 4.4% by the end of 2032.
The development of pacemakers and minimally invasive vessel treatment together are enhancing the growth of the market. Pacemakers are usually used in the treatment of second degree heart blocks and third degree heart blocks.
Globally, there are about 3 Mn people using pacemakers, and every year around 600 thousand pacemakers are implanted. Market revenue through pacemakers has witnessed a CAGR growth of 4.8% from 2015 to 2021, and the projected CAGR through this category is expected to be 4.2% by 2032.
At present, the Heart Block Therapeutics market is moderately competitive and has numerous players. There are only a few key players which dominate the market and have a much wider geographic presence and improved research and development resources ensuing in robust regulatory approvals.
The key companies operating in the Heart Block Therapeutics Market are St. Jude Medical, Medtronic, Bristol Myers Squibb, Novartis AG, Boston Scientific Corporation, SORIN S.p.A, BIOTRONIK SE & Co. KG, Edward Lifesciences Corporation, Abbott Laboratories, Natco Pharma, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., Astra Zeneca, Sanofi, Merck & Co., Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd.
Some of the recent developments by the key providers of Heart Block Therapeutics are as follows:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Attributes | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2017 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, Russia, China, Japan, South Korea, India, Australia, South Africa, Saudi Arabia, UAE and Israel |
| Key Market Segments Covered | Type, Product, End User, Region |
| Key Companies Profiled |
|
| Report Coverage | Value (In US$ Billion) |
| Customization & Pricing | Available upon Request |
The global Heart Block Therapeutics Market was valued at US$ 3 Bn in 2021 and is expected to grow 1.5X by 2032.
Over the projected period, the Heart Block Therapeutics Market is expected to increase at a rate of 4.3%, reaching a value of US$ 4.8 Bn by 2032.
The involvement of technology in Heart Block therapeutics has been adding significant revenues to the market.
The Heart Block Therapeutics Market expanded at 4.9% from 2015 through 2021.
Pacemakers are the top product in the Heart Block Therapy Industry. Heart block treatment market revenue through this category expanded at a CAGR of 4.8% from 2015 to 2021, and is projected to grow at a CAGR of 4.2% by 2032.
Medtronic, Novartis AG, Boston Scientific Corporation, SORIN S.p.A, and Bristol Myers Squibb, are some of the key players in the Heart Block Therapeutics Industry.
The US, UK, China, Japan and South Korea are expected to drive the most Heart Block Therapeuticss.
The US has the largest market for Heart Block Therapeutics.
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. FMI Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Heart Block Therapeutics 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background 4.1. Heart Block Therapeutics Market, by Key Countries 4.2. Heart Block Therapeutics Market Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Growth in Automation, By Country 4.5.3. Patch Management Adoption Rate, By Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Patch Management Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Heart Block Therapeutics Market Demand Analysis 2015-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2015-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Heart Block Therapeutics Market Value Analysis 2015-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032, By Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Type, 2015-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2022-2032 8.3.1. First-degree heart blocks 8.3.2. Second-degree heart blocks 8.3.3. Third-degree heart blocks 8.4. Market Attractiveness Analysis By Type 9. Global Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Product, 2015-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032 9.3.1. Transcutaneous pacing (TCP) 9.3.2. Pacemaker 9.3.3. Mediation 9.3.4. Follow-up electrophysiology study 9.4. Market Attractiveness Analysis By Product 10. Global Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By End User, 2015-2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032 10.3.1. Hospital testing 10.3.2. Home treatment 10.3.3. Clinics 10.3.4. Others 10.4. Market Attractiveness Analysis By End User 11. Global Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021 11.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Asia Pacific 11.3.5. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 12.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. U.S. 12.4.1.2. Canada 12.4.1.3. Rest of North America 12.4.2. By Type 12.4.3. By End User 12.4.4. By Product 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Type 12.5.3. By End User 12.5.4. By Product 13. Latin America Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 13.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. Brazil 13.4.1.2. Mexico 13.4.1.3. Rest of Latin America 13.4.2. By Type 13.4.3. By End User 13.4.4. By Product 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Type 13.5.3. By End User 13.5.4. By Product 14. Europe Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 14.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. Germany 14.4.1.2. France 14.4.1.3. U.K. 14.4.1.4. Italy 14.4.1.5. Benelux 14.4.1.6. Nordic Countries 14.4.1.7. Rest of Europe 14.4.2. By Type 14.4.3. By End User 14.4.4. By Product 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Type 14.5.3. By End User 14.5.4. By Product 15. Asia Pacific Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 15.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 15.4.1. By Country 15.4.1.1. China 15.4.1.2. Japan 15.4.1.3. South Korea 15.4.1.4. Rest of Asia Pacific 15.4.2. By Type 15.4.3. By End User 15.4.4. By Product 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Type 15.5.3. By End User 15.5.4. By Product 16. Middle East and Africa Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 16.4. Market Size (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 16.4.1. By Country 16.4.1.1. GCC Countries 16.4.1.2. South Africa 16.4.1.3. Turkey 16.4.1.4. Rest of Middle East and Africa 16.4.2. By Type 16.4.3. By End User 16.4.4. By Product 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Type 16.5.3. By End User 16.5.4. By Product 17. Key Countries Heart Block Therapeutics Market Analysis 2015-2021 and Forecast 2022-2032 17.1. Introduction 17.1.1. Market Value Proportion Analysis, By Key Countries 17.1.2. Global Vs. Country Growth Comparison 17.2. US Heart Block Therapeutics Market Analysis 17.2.1. Value Proportion Analysis by Market Taxonomy 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.2.2.1. By Type 17.2.2.2. By End User 17.2.2.3. By Product 17.3. Canada Heart Block Therapeutics Market Analysis 17.3.1. Value Proportion Analysis by Market Taxonomy 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.3.2.1. By Type 17.3.2.2. By End User 17.3.2.3. By Product 17.4. Mexico Heart Block Therapeutics Market Analysis 17.4.1. Value Proportion Analysis by Market Taxonomy 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.4.2.1. By Type 17.4.2.2. By End User 17.4.2.3. By Product 17.5. Brazil Heart Block Therapeutics Market Analysis 17.5.1. Value Proportion Analysis by Market Taxonomy 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.5.2.1. By Type 17.5.2.2. By End User 17.5.2.3. By Product 17.6. Germany Heart Block Therapeutics Market Analysis 17.6.1. Value Proportion Analysis by Market Taxonomy 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.6.2.1. By Type 17.6.2.2. By End User 17.6.2.3. By Product 17.7. France Heart Block Therapeutics Market Analysis 17.7.1. Value Proportion Analysis by Market Taxonomy 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.7.2.1. By Type 17.7.2.2. By End User 17.7.2.3. By Product 17.8. Italy Heart Block Therapeutics Market Analysis 17.8.1. Value Proportion Analysis by Market Taxonomy 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.8.2.1. By Type 17.8.2.2. By End User 17.8.2.3. By Product 17.9. BENELUX Heart Block Therapeutics Market Analysis 17.9.1. Value Proportion Analysis by Market Taxonomy 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.9.2.1. By Type 17.9.2.2. By End User 17.9.2.3. By Product 17.10. UK Heart Block Therapeutics Market Analysis 17.10.1. Value Proportion Analysis by Market Taxonomy 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.10.2.1. By Type 17.10.2.2. By End User 17.10.2.3. By Product 17.11. Nordic Countries Heart Block Therapeutics Market Analysis 17.11.1. Value Proportion Analysis by Market Taxonomy 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.11.2.1. By Type 17.11.2.2. By End User 17.11.2.3. By Product 17.12. China Heart Block Therapeutics Market Analysis 17.12.1. Value Proportion Analysis by Market Taxonomy 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.12.2.1. By Type 17.12.2.2. By End User 17.12.2.3. By Product 17.13. Japan Heart Block Therapeutics Market Analysis 17.13.1. Value Proportion Analysis by Market Taxonomy 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.13.2.1. By Type 17.13.2.2. By End User 17.13.2.3. By Product 17.14. South Korea Heart Block Therapeutics Market Analysis 17.14.1. Value Proportion Analysis by Market Taxonomy 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.14.2.1. By Type 17.14.2.2. By End User 17.14.2.3. By Product 17.15. GCC Countries Heart Block Therapeutics Market Analysis 17.15.1. Value Proportion Analysis by Market Taxonomy 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.15.2.1. By Type 17.15.2.2. By End User 17.15.2.3. By Product 17.16. South Africa Heart Block Therapeutics Market Analysis 17.16.1. Value Proportion Analysis by Market Taxonomy 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.16.2.1. By Type 17.16.2.2. By End User 17.16.2.3. By Product 17.17. Turkey Heart Block Therapeutics Market Analysis 17.17.1. Value Proportion Analysis by Market Taxonomy 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 17.17.2.1. By Type 17.17.2.2. By End User 17.17.2.3. By Product 17.17.3. Competition Landscape and Player Concentration in the Country 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 18.4.1. By Regional footprint of Players 18.4.2. Product footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Competition Deep Dive 19.3.1. Medtronic 19.3.1.1. Overview 19.3.1.2. Product Portfolio 19.3.1.3. Sales Footprint 19.3.1.4. Strategy Overview 19.3.2. Abbott 19.3.2.1. Overview 19.3.2.2. Product Portfolio 19.3.2.3. Sales Footprint 19.3.2.4. Strategy Overview 19.3.3. MicroPort Scientific Corporation 19.3.3.1. Overview 19.3.3.2. Product Portfolio 19.3.3.3. Sales Footprint 19.3.3.4. Strategy Overview 19.3.4. Koninklijke Philips N.V. 19.3.4.1. Overview 19.3.4.2. Product Portfolio 19.3.4.3. Sales Footprint 19.3.4.4. Strategy Overview 19.3.5. Boston Scientific Corporation 19.3.5.1. Overview 19.3.5.2. Product Portfolio 19.3.5.3. Sales Footprint 19.3.5.4. Strategy Overview 19.3.6. LivaNova PLC 19.3.6.1. Overview 19.3.6.2. Product Portfolio 19.3.6.3. Sales Footprint 19.3.6.4. Strategy Overview 19.3.7. Lepu Medical Technology (Beijing) Co., Ltd., 19.3.7.1. Overview 19.3.7.2. Product Portfolio 19.3.7.3. Sales Footprint 19.3.7.4. Strategy Overview 19.3.8. McKesson Corporation 19.3.8.1. Overview 19.3.8.2. Product Portfolio 19.3.8.3. Sales Footprint 19.3.8.4. Strategy Overview 19.3.9. Stryker 19.3.9.1. Overview 19.3.9.2. Product Portfolio 19.3.9.3. Sales Footprint 19.3.9.4. Strategy Overview 19.3.10. Cigna 19.3.10.1. Overview 19.3.10.2. Product Portfolio 19.3.10.3. Sales Footprint 19.3.10.4. Strategy Overview 19.3.11. Shree Pacetronix Ltd. 19.3.11.1. Overview 19.3.11.2. Product Portfolio 19.3.11.3. Sales Footprint 19.3.11.4. Strategy Overview 19.3.12. ZOLL Medical Corporation 19.3.12.1. Overview 19.3.12.2. Product Portfolio 19.3.12.3. Sales Footprint 19.3.12.4. Strategy Overview 19.3.13. GENERAL ELECTRIC COMPANY 19.3.13.1. Overview 19.3.13.2. Product Portfolio 19.3.13.3. Sales Footprint 19.3.13.4. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Heart Block Therapeutics Market
